Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1221-1240 of 1,743 trials

Duchenne Muscular Dystrophy: SGT-003 Gene Therapy

We are studying a new gene therapy to see if it is safe and effective for males with Duchenne Muscular Dystrophy. The trial will assess improvements in muscle function and other health measures after a single intravenous dose.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Heart Failure Risk: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin can lower the risk of heart failure and cardiovascular death in people at increased risk. This trial compares this combination to dapagliflozin alone.

Heart Failure Signs and Symptoms>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyInternal Medicine

Familial Hypercholesterolemia: Inclisiran vs. Alirocumab

We are comparing two new treatments, inclisiran and alirocumab, to standard therapy for children with heterozygous familial hypercholesterolemia. The goal is to see which treatment better lowers cholesterol levels and improves quality of life.

Heterozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyEndocrinology

Acute Myeloid Leukemia: SNDX-5613 with Chemotherapy

We are testing a new drug, SNDX-5613, combined with intensive chemotherapy for patients with AML who have certain genetic changes. The goal is to see if this combination improves treatment outcomes.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

B-Cell Lymphoma: TranspoCART19 T Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory B-cell lymphoma. The trial aims to evaluate the safety and effectiveness of this therapy in improving patient outcomes.

Relapsed or Refractory B-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Atopic Dermatitis: Methylprednisolone Aceponate Ointment

We are comparing a new ointment for atopic dermatitis with an existing treatment and a placebo. The goal is to see how well it reduces skin symptoms like itching and redness.

Mild to Moderate Atopic Dermatitis>2 yearsSafety phase (I)Investigational MedicinesAllergologyDermatology

OMX-0407 for Unresectable Solid Tumors

We are studying a new medication, OMX-0407, in patients with previously treated solid tumors to see how well it works and to find the safest dose. This trial will help us understand its effects on cancer response and patient quality of life.

Previously Treated Unresectable Solid Tumours>2 yearsSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Colon Cancer: New Treatment with PIPAC

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard treatments improves outcomes for patients with advanced colon cancer that has spread to the abdomen. This trial will help us understand its effects on survival and quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Subarachnoid Hemorrhage: EDV2209 Medication Study

We are investigating the safety and tolerability of a new medication, EDV2209, for patients with bleeding in the brain. This study compares the effects of EDV2209 to a placebo to see how it may help in recovery.

Subarachnoid Hemorrhage>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurology

T-Cell Acute Lymphoblastic Leukemia: OC-1 CAR T Therapy

We are studying the safety and effectiveness of OC-1 therapy for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoma. This trial aims to understand how well the treatment works and its impact on patient survival.

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Inclisiran for Children with High Cholesterol

We are studying the safety and effectiveness of inclisiran in children aged 2 to under 12 years with homozygous familial hypercholesterolemia. The goal is to see if it can lower their cholesterol levels compared to a placebo.

Homozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Thyroid Cancer Treatment: Radioiodine Strategies

We are comparing two treatment strategies for intermediate-risk differentiated thyroid cancer patients to see which is more effective. This study will also evaluate patient quality of life and side effects over time.

Thyroid Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Sarcoidosis: Oral Sirolimus for Facial Skin Involvement

We are studying whether sirolimus can improve facial skin symptoms in patients with sarcoidosis. The trial also examines its effects on quality of life and overall skin health.

Skin Sarcoidosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesAllergologyDermatology

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Immune Response Study: Posdinemab

We are examining how the immune system reacts in participants who received Posdinemab. This research aims to improve our understanding of its effects on the immune system.

Alzheimer's Disease>2 yearsSafety phase (I)Neurology

Seminomas: EDEN Study on Reduced Therapy

We are testing a less intense treatment for patients with stage IIa/IIb seminomas under 3 cm to see if it helps prevent relapse. We’re also evaluating a biomarker to understand treatment response and its effects on quality of life.

Stage IIa/IIb Seminoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Oxygen Support Methods for High-Risk Patients

We are comparing non-invasive ventilation and high flow oxygen therapy for patients at high risk of needing reintubation. The goal is to see which method better helps patients recover and reduces complications.

Weaning Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePulmonology

Plaque Psoriasis: Bimekizumab vs. Topical Corticosteroids

We are studying whether bimekizumab can better control plaque psoriasis compared to standard topical treatments. This trial aims to improve disease management and quality of life for patients.

Eruptive Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Chronic Lymphocytic Leukemia: Venetoclax with Ibrutinib and Rituximab

We are studying a combination of venetoclax, rituximab, and ibrutinib for treatment-naïve patients with chronic lymphocytic leukemia. The aim is to see if this approach can lead to undetectable minimal residual disease.

Chronic Lymphocytic Leukaemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology